Skip to main content
Philip Dormitzer, MD, Internal Medicine, Cambridge, MA, South Shore Hospital

PhilipR.DormitzerMDPhD

Internal Medicine • Cambridge, MA

Hospital Medicine/Hospitalist

Head of US Research, Global Head of Virology, Vice President, Novartis Vaccines; Hospitalist, Coastal Medical Assoc.

Join to view full profile

Dr. Dormitzer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Dormitzer's full profile

Already have an account?

Summary

  • Philip R. Dormitzer, M.D., Ph.D., is Head of US Research, Global Head of Virology, and Vice President at Novartis Vaccines and Diagnostics in Cambridge, Massachusetts. He is a practicing physician, board certified in Internal Medicine. After studying anthropology at Harvard College and carrying out a field study of the Efe Pygmies in the Ituri Forest of Zaire, Dr. Dormitzer completed his M.D. and Ph.D. degrees at Stanford University. His graduate research focused on rotavirus antigenic structure. Dr. Dormitzer completed house-staff training in Internal Medicine at Massachusetts General Hospital and a fellowship in the Harvard Combined Infectious Diseases Training Program. He conducted his fellowship research in the Laboratory of Molecular Medicine, led by Dr. Stephen Harrison. As an Assistant Professor of Pediatrics at Harvard Medical School, Dr. Dormitzer led a structural virology laboratory. The Dormitzer group and its collaborators determined the structures of the rotavirus neutralization antigens by NMR spectroscopy, X-ray crystallography, and near atomic resolution electron cryomicroscopy. At NV&D, as Senior Project Leader for Viral Vaccine Research, he had responsibility for global vaccine research projects on influenza, RSV, parvovirus B19, and other agents. In 2009, these projects included the research component of the Novartis response to the H1N1v influenza pandemic, supporting the development and licensure of three pandemic influenza vaccines in the most rapid vaccine response in history. As Head of the Viral Advanced Programs Global Team, he coordinated scientific and industrial functions to advance novel viral vaccine projects toward licensure, with a primary focus on an engineered RSV F subunit vaccine candidate, intended for maternal immunization. As Head of Research, US, he leads approximately 80 scientists, most based at the NV&D Cambridge Research Center, in their viral vaccine discovery mission.

Education & Training

  • Harvard Combined Program in Infectious Diseases
    Harvard Combined Program in Infectious Diseases1996 - 2000
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1995 - 1996
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1994 - 1995
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1994, MD
  • Stanford University
    Stanford University PhD, Cancer Biology, 1987 - 1992
  • Harvard University
    Harvard UniversityB.A., Biological Anthropology, summa cum laude, 1980 - 1986

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1996 - 2025
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Maxwell Finland Award for scientific excellence during an infectious disease fellowship Massachusetts Infectious Disease Society, 2000
  • Joseph Garrison Parker Prize for breadth of interest in a pre-medical student Harvard College, 1986
  • Jacob Wendell Scholar for academic promise based on the record of the freshman year Harvard College, 1981

Publications & Presentations

PubMed

Journal Articles

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine  
    Fernando P Polack, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kenneth Koury, Robert W Frenck, Philip R Dormitzer, The New England Journal of Medicine
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates  
    Edward E Walsh, Robert W Frenck, Ann R Falsey, Judith Absalon, Kathleen Neuzil, Vanessa Raabe, Philip R Dormitzer, The New England Journal of Medicine
  • Intra-Seasonal Antibody Repertoire Analysis of a Subject Immunized with an MF59®-Adjuvanted Pandemic 2009 H1N1 Vaccine  
    M Anthony Moody, Philip R Dormitzer, Stephen C Harrison, ScienceDirect

Books/Book Chapters

  • Virus Taxonomoy. Ninth Report of the International Committee on the Taxonomy of Viruses 
    Chapter: Family Reoviridae 
    Page 541 - 637Attoui, H., P.P.C. Mertens, J. Becnel, S. Belaganahalli, M. Bergoin, C.P. Brussaard, J.D. Chappell, M. Ciarlet, M. del Vas, T.S. Dermody, P.R. Dormitzer, R. Duncan, Q....Editors: King, A.M.Q., M.J. Adams, E.B. Carstens, and E.J. Lefkowitz.Elsevier Academic Press, London
  • Influenza Vaccines for the Future 
    Chapter: Cell culture-derived influenza vaccines 
    Page 293 - 312Dormitzer, P.R.Editors: G. Del Giudice and R. Rappuoli.Birkhauser, BaselEdition 2nd,
  • The Oxford Textbook of Medicine 
    Chapter: Virus infections causing dirrhoea and vomiting 
    Dormitzer, P., and U. DesselbergerEditors: Warrell, D., T. Cox, and J. Firth.Oxford University Press, Oxford, U.K.Edition 5th,
  • Join now to see all

Other

  • The Antigenicity and Imunogenicity of Rotavirus Outer Capsid Proteins Expressed by Novel Recombinant Herpesvirus Vectors 
    Dormitzer, P.R., Ph.D. Thesis, Program in Cancer Biology, Stanford University
    University Microfilms, Inc., Ann Arbor, MI

Press Mentions

  • Maintaining Warp Speed: Policy Requirements for a Just-in-Time, Capability-Based, Scalable Medical Countermeasure Research and Development Enterprise
    Maintaining Warp Speed: Policy Requirements for a Just-in-Time, Capability-Based, Scalable Medical Countermeasure Research and Development EnterpriseMay 18th, 2023
  • IDSA Honors 175 Distinguished Physicians, Scientists with FIDSA Designation
    IDSA Honors 175 Distinguished Physicians, Scientists with FIDSA DesignationAugust 17th, 2022
  • COVID Vaccine Makers Prepare for a Variant Worse Than Delta
    COVID Vaccine Makers Prepare for a Variant Worse Than DeltaOctober 25th, 2021
  • Join now to see all

Grant Support

  • Synthetic Influenza Vaccine Seeds for Rapid Pandemic ResponseBiomedical Advanced Research and Development Authority2010–Present
  • Manipulating Immunodominance In Influenza HANational Institute Of Allergy And Infectious Diseases2011
  • Rotavirus Vp4: Structure And FunctionNational Institute Of Allergy And Infectious Diseases2003–2006
  • Structural Basis For Rotavirus Entry Into CellsNational Institute Of Allergy And Infectious Diseases1998–2000

Committees

  • Member, Research Committee, Infectious Diseases Society of America 2012 - Present
  • Member, Editorial Board, Journal of Virology

Professional Memberships

Hospital Affiliations

Dr. Philip Dormitzer, Dr. Philip Dormitzer, MD, Dr. P Dormitzer, Dr. Philip R. Dormitzer